Canaccord Genuity analyst Adam Walsh weighed in with an optimistic view on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), reiterating a Buy recommendation on the stock with …
On May 19, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced plans to complete a New Drug Application (NDA) for eteplirsen, Sarepta’s lead product candidate. SRPT …
On May 12, the FDA advisory committee recommended that the FDA approve Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s Orkambi therapy to treat cystic fibrosis. Shares of …
In a research report released Friday, Canaccord Genuity analyst Adam Walsh initiated coverage on shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a Buy rating and …
In a research report published this morning, Canaccord Genuity analyst Adam Walsh maintained a Hold rating on Sarepta Therapeutics Inc (NASDAQ:SRPT) with a $16 price …
In a research report sent to investors today, Canaccord Genuity analyst Adam Walsh initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) with a …
